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Abstract:
Drug resistance is a substantial clinical problem, with combination therapies often the only recourse. Here, we propose a novel antiviral approach that disrupts viral auto-regulatory circuits, which limits resistance by requiring multiple viral mutations. We provide proof-of-concept that DNA-based circuit-disruptor oligonucleotide therapies (C-DOTs) interfere with transcriptional 5 negative feedback in human herpesviruses (CMV and HSV-1) thereby increasing viral transcription factors to cytotoxic levels. C-DOTs reduce viral replication >100-fold, are effective in high-viremic conditions where existing antivirals are ineffective, and show efficacy in mice. Strikingly, no C-DOT-resistant mutants evolved in >60 days of culture, in contrast to approved herpesvirus antivirals where resistance rapidly evolved. Oligonucleotide therapies that 10 target feedback circuits could mimic combination therapy and represent escape-resistant interventions with broad applicability to viruses, microbes, and neoplastic cells.
One Sentence Summary:
A single oligonucleotide breaks transcriptional feedback and mimics combination therapy to 15 limit the emergence of antiviral resistance.
Main text:
From bacteria to cancers, drug resistance arising from 'escape' mutations causes substantial morbidity and mortality (1) (2) (3) . The time to escape mutant arisal can be estimated from the mutation rate, µ, and the effective population size, N, (4, 5) and many viruses exhibit large µ such that frequency of mutants (µ´N) is >1 even for moderate virus population sizes (e.g., if 5 µ~10 -5 then for µ´N > 1 only requires N > 10 5 ). Herpesviruses, for example, exhibit high mutation rates (6, 7) , which may explain the substantial antiviral resistance observed in clinical settings (8, 9) . In particular, herpes simplex virus type 1 (HSV-1)-a leading cause of blindness-exhibits resistance to acyclovir (ACV) in ~40% of transplant patients (10) while human herpesvirus 5, cytomegalovirus (CMV)-a leading cause of birth defects and transplant 10 failure-exhibits resistance to ganciclovir (GCV) in 30-75% of patients (11) . ACV and GCV resistance arises because their antiviral activity requires herpesvirus thymidine kinase (TK), and single-base mutations destroy TK activity with a µ ~10 -3 (6) driving TK escape mutants within a single generation (12) , which ultimately promoted the development of non-TK drug targets (13, 14) . Resistance to these new therapies is still being clinically evaluated, but, given the generality 15 of resistance to antimicrobials (1-3), is likely unavoidable.
Combination therapy, wherein multiple drugs simultaneously inhibit different viral targets, is one approach used to limit antiviral resistance. For a two-drug therapy, escape mutants are predicted to arise at a rate ~µ 2 (i.e., the requirement for mutants to arise becomes µ 2 ×N > 1), which requires 20 substantially larger virus populations (i.e., N >µ -2 ). However, each constituent antiviral must have a distinct molecular target, as well as favorable toxicity, efficacy, bioavailability, and dosing profiles. These criteria can be challenging to satisfy and such targets are still being characterized for herpesviruses. One proposed alternative has been to mimic the evolutionary benefits of combination therapy by inhibiting protein-protein or protein-DNA interactions with a single molecule; this has remained technically challenging but transcriptional auto-regulatory (feedback) circuits present an attractive target for this approach (15) . Both CMV and HSV-1 5 utilize transcriptional feedback to regulate immediate-early (IE) viral gene expression, which is obligate to transactivate downstream viral genes, ultimately licensing virus maturation (16) (17) (18) (19) .
In CMV, the 86-kDa immediate early (IE86; a.k.a. IE2) protein, and in HSV-1 the IE175 (a.k.a. ICP4) protein, are indispensable transcriptional transactivators (20, 21) . Critically, IE86 and IE175 are cytotoxic when expression is misregulated above tightly auto-regulated homeostatic 10 levels, and both CMV and HSV-1 encode negative-feedback circuits to maintain IE86 and IE175 levels below their respective cytotoxic thresholds (20, 22) . These feedback circuits are comprised of a protein-DNA interaction wherein the IE protein binds to a 14-15 bp palindromic cis-repression sequence (crs) within its respective promoter and auto-represses its own transcription ( Fig. 1A ). Disrupting this feedback by altering the crs increases IE protein levels to 15 cytotoxic levels, leading to a >100-fold reduction in viral replication (22, 23).
We hypothesized that oligonucleotides mimicking the palindromic DNA-binding site could titrate IE proteins away from the crs and act as competitive inhibitors to disrupt IE negative feedback ( Fig. 1A) .
Mathematical modeling predicted that such circuit-disrupting 20 oligonucleotide therapies (C-DOTs) may in fact raise IE protein to cytotoxic levels ( Fig. 1B and fig. S1). Theoretically, to escape C-DOTs and recapitulate a feedback loop, the virus would need to evolve a new IE-protein domain to recognize a new DNA sequence and simultaneously evolve a new cognate DNA binding sequence in the IE promoter; these C-DOT escape mutants would evolve on order of µ 2 , which would occur substantially slower than observed for ACV/GCV resistance (Fig. 1C ). It is conceivable that single mutants in the IE protein could arise and bind alternate crs-like sequences pre-existing in the promoter region, thereby circumventing the combinatorial mutation hypothesis. However, there are no comparable palindromes within 5 500 bp of the MIEP promoter and if such sequences were present, then crs-deletion mutants should strongly select for such IE86 mutants that can recapitulate negative feedback, which does not occur over ~1 month of culturing (22).
To find oligonucleotides that optimally titrate IE proteins, we developed an in vitro liquid-10 chromatography assay to quantify the efficiency of various linear DNA oligonucleotides in catalyzing formation of the IE86 protein-DNA complex ( Fig. 2A ). To validate the assay, we To test if these DNAs disrupted negative feedback, we used a retinal pigment epithelial cell line 20 stably transduced with a previously described minimal IE86 negative-feedback reporter circuit Next, we investigated the effects of disrupting transcriptional feedback in the context of viral infection. We designated the 28bp DNA for CMV IE86 as C-DOT C (C-DOT for CMV) and found that C-DOT C efficiently disrupted IE86 negative feedback in cells infected with a clinically-derived isolate of CMV (24) (Fig. 3A) . We next hypothesized that replacing the 14bp crs within C-DOT C with the 15bp repression sequence from IE175's promoter could generate a 15 C-DOT for HSV-1 (now termed C-DOT H ). As predicted, C-DOT H disrupted IE175 negative feedback in cells infected with clinically-derived HSV-1 (25) ( Fig. 3B ). There was minimal difference in %IE positive cells, indicating that C-DOTs did not alter permissiveness of cells to viral infection ( fig. S6 ). Strikingly, the C-DOTs also reduced single-round viral replication titers for both CMV and HSV-1 at multiplicity of infection (MOI) of 0.1 by ~100 fold (Fig. 3C-D) , in 20 agreement with genetic disruption of IE negative feedback (22). To be sure that the observed antiviral effects were not specific to the virus strain or cell type used, we also tested (i) CMV strain AD169 and (ii) various GCV-resistant CMV strains in human foreskin fibroblasts, as well as (iii) murine CMV and (iv) rhesus CMV, in mouse and primate cells respectively, and in all cases found similar 100-fold titer reduction using the corresponding C-DOTs (figs. S7-S8).
In stark contrast to ACV and GCV, C-DOT increases virus fold reduction at higher MOI, and, at MOI = 2, C-DOTs exhibited a > 1300x reduction whereas ACV/GCV elicited 35-70x reduction 5 in viral replication ( Fig. 3C-D) . Such robustness to high-viremic conditions has not been previously described for an antiviral (26), but is consistent with the putative C-DOT mechanism of action through feedback disruption and IE-mediated cytotoxicity-higher MOIs deliver more genomes, which generates more potentially cytotoxic IE protein. Next, to examine the rate of emergence of viral escape mutants, we used a continuous-culture 20 approach where virus was consecutively passaged from infected cells to fresh uninfected cells every 4 days (a typical CMV replication round) until virus was undetectable in presence of C-DOT treatment (~40-60 days; Fig. 3E ). C-DOT C was compared to Fomivirsen (28), the first approved DNA oligonucleotide therapy (an anti-sense DNA for IE86); C-DOT H was compared with ACV ( fig. S11 ). As previously reported (12), we found HSV-1 resistance to ACV emerges within two rounds of infection ( fig. S11C ) and that CMV resistance to Fomivirsen (28) arises within 3-4 rounds of infection ( fig. S11A-B ).
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In striking contrast, C-DOT C steadily reduced CMV titers to below the limit of detection by day 52, with no evidence of CMV resistance to the C-DOT C (Fig. 3F and fig. S12) . Similarly, C-DOT H steadily reduced HSV-1 titers to below detection by day 40, with no evidence of resistance ( Fig. 3G ). Subsequent sub-culturing indicated that virus was cleared and that pre- Finally, we tested if transcriptional feedback could be disrupted in vivo using the established model of herpes infection in mice (29) . Briefly, in this model, mice are infected with HSV-1 in the cornea, and interventions are topically applied at the site of infection to test efficacy. Using standard practice, we infected mice with HSV-1 IE175-YFP, then 6 hours later (to avoid 20 interfering with virus uptake), oligonucleotides were applied and after two days, corneas were harvested for imaging and quantification of viral replication by q-PCR and titering (Fig. 4A ). C-DOT uptake by cells was quantified by Cy3 fluorescence (fig. S16A) and as predicted, C-DOT treatment first caused an increase in IE175 (fig. S16B) followed by a significant reduction in the percentage of HSV-1 infected cells ( Fig. 4B-C) . In agreement with these data, C-DOT H treatment reduced viral titer by 150-fold ( Fig. 4D ) and significantly reduced viral genome replication (Fig. 4E ). Together, these results demonstrate that feedback disruption reduces viral replication in vivo. 5
Overall, these results indicate that transcriptional feedback could represent a new antiviral target with the potential to substantially delay the emergence of resistance ( Fig. 3 ) and overcome significant treatment barriers including the reduction-in-efficacy at high-viremic loads (26). In general, oligonucleotide therapies offer specificity with the potential for fewer off target effects over small molecules. Delivery of oligonucleotides remains a major challenge but significant 10 clinical advances have been made with the recent FDA approval of antisense and exon-skipping oligonucleotide therapies delivered via nanoparticles (30) (31) (32) . We also tested C-DOTs using nanoparticle carriers, in the absence of transfection, and found similar antiviral effects (fig. S17).
One could envision nanoparticles harboring combinatorial C-DOTs to treat infections of unknown etiology-a significant problem for ocular infections (33, 34) . Our data indicate that 15 such combinatorial C-DOTs may be feasible ( fig. S18 ).
From the perspective of resistance, disrupting transcriptional feedback limits escape mutations by reducing the potential of generation of mutants and their selection. First, the IE region has a far lower µ than TK (6, 35) such that mutants in the IE promoter and IE coding regions will arise 20 slowly. Second, our assumption that mutants arise at ~µ 2 is maximally conservative and based on two single-base mutations being sufficient to recapitulate feedback-one mutation in the promoter to generate a new binding sequence for the new IE protein and one mutation in the 10 protein to generate a new recognition domain to bind the new DNA site. It is likely that > 2 mutations will be required for a new protein recognition domain. So, escape mutants will likely arise at the far slower rate of ~µ n (where n > 2). For CMV, with an average µ~10 -4 (7) this translates to feedback-disruptor escape mutants arising slower than ~10 -4n (assuming the IE region follows the average mutation frequency, whereas IE mutation frequency is in fact lower). 5
Regarding selection, the single mutants that do not recapitulate feedback-likely prerequisites for the multiple mutants-have no selective advantage in the presence (or absence) of feedback disruptors. Moreover, prior to feedback disruption, putative C-DOT escape mutants (with perfect feedback recapitulation) would have a relative fitness roughly equivalent to wild type, so their selection coefficient will be small (far lower than for TK mutants s C-DOT << s TK ) and their 10 arisal time slow. Consequently, the calculations above (Fig. 1C) represent an extreme lower limit for the time to escape from feedback disruptors. We predict that this proof-of-principle based on transcription disruption in herpesviruses could be extended to other viruses, microbes, and even aberrant transcriptional auto-regulatory circuits in neoplastic cells. 
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Figures S1-S18 emergence of resistance to GCV in the clinic (11) is shown as a point above the measured TK mutation rate (µ = 10 -4 ). Putative C-DOT resistance, predicted to require at least two mutations (one in the protein and one in the promoter), is shown as a line corresponding to measured µ (7) .
Inset: representative dynamics of emergence for either a GCV mutant (black) or a putative C-DOT mutant (cyan) that requires only viral two mutations. See Methods for equations. 20 
